Literature DB >> 26721621

Amyloid β-interacting partners in Alzheimer's disease: From accomplices to possible therapeutic targets.

Sun-Ho Han1, Jong-Chan Park1, Inhee Mook-Jung2.   

Abstract

Alzheimer's disease (AD) is one of the most devastating neurodegenerative diseases in modern society because of insurmountable difficulties in early diagnosis and lack of therapeutic treatments. AD pathogenesis is tightly linked to the abnormal accumulation and aggregation of amyloid β (Aβ), seemingly the main causative factor of AD; however, intensive research on Aβ has not yet explained the complexity of AD pathogenesis. Consequently, the role of other supportive partners of Aβ have been elucidated and evaluated in the etiology of AD, and their potential molecular mechanisms have emerged as possible therapeutic targets. In this review, we compile information regarding Aβ-interacting partners in normal conditions and AD pathology, and analyze their etiological roles in diverse areas. Furthermore, we integrate this information into suggestions for probable clinical applications for AD diagnosis and therapeutics. We include Aβ-interacting partners localized to the cell surface and intracellular and extracellular compartments of different cell types ranging from the central nervous system to peripheral regions. Additionally, we expand the range of Aβ-interacting partners by including not only proteins, but also inorganic substances like metals, expecting that one of these partners may yield a critical breakthrough in the field of AD diagnostics and therapeutic drug development.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Amyloid β; Amyloid β-interacting protein; Blood–brain barrier; Cerebrospinal fluid

Mesh:

Substances:

Year:  2015        PMID: 26721621     DOI: 10.1016/j.pneurobio.2015.12.004

Source DB:  PubMed          Journal:  Prog Neurobiol        ISSN: 0301-0082            Impact factor:   11.685


  23 in total

1.  N2L, a novel lipoic acid-niacin dimer protects HT22 cells against β-amyloid peptide-induced damage through attenuating apoptosis.

Authors:  Rikang Wang; Lang Zhang; Rifang Liao; Qian Li; Rongbiao Pi; Xiaobo Yang
Journal:  Metab Brain Dis       Date:  2019-09-02       Impact factor: 3.584

Review 2.  Regulation of the alternative β-secretase meprin β by ADAM-mediated shedding.

Authors:  Franka Scharfenberg; Fred Armbrust; Liana Marengo; Claus Pietrzik; Christoph Becker-Pauly
Journal:  Cell Mol Life Sci       Date:  2019-06-14       Impact factor: 9.261

Review 3.  Stressed and Inflamed, Can GSK3 Be Blamed?

Authors:  Richard S Jope; Yuyan Cheng; Jeffrey A Lowell; Ryan J Worthen; Yoel H Sitbon; Eleonore Beurel
Journal:  Trends Biochem Sci       Date:  2016-11-19       Impact factor: 13.807

Review 4.  Apolipoprotein E metabolism and functions in brain and its role in Alzheimer's disease.

Authors:  Fan Liao; Hyejin Yoon; Jungsu Kim
Journal:  Curr Opin Lipidol       Date:  2017-02       Impact factor: 4.776

5.  Targeting Apolipoprotein E/Amyloid β Binding by Peptoid CPO_Aβ17-21 P Ameliorates Alzheimer's Disease Related Pathology and Cognitive Decline.

Authors:  Shan Liu; Shinae Park; Grant Allington; Frances Prelli; Yanjie Sun; Mitchell Martá-Ariza; Henrieta Scholtzova; Goutam Biswas; Bernard Brown; Philip B Verghese; Pankaj D Mehta; Yong-Uk Kwon; Thomas Wisniewski
Journal:  Sci Rep       Date:  2017-08-14       Impact factor: 4.379

6.  Artemisinin protects PC12 cells against β-amyloid-induced apoptosis through activation of the ERK1/2 signaling pathway.

Authors:  Zhiwen Zeng; Jinying Xu; Wenhua Zheng
Journal:  Redox Biol       Date:  2017-04-04       Impact factor: 11.799

7.  PRAK mediates Aβ-RAGE driven autophagy pathway.

Authors:  Yoonhee Kim; Inhee Mook-Jung
Journal:  Oncotarget       Date:  2017-01-24

8.  Chemically treated plasma Aβ is a potential blood-based biomarker for screening cerebral amyloid deposition.

Authors:  Jong-Chan Park; Sun-Ho Han; Hyun Jin Cho; Min Soo Byun; Dahyun Yi; Young Min Choe; Seokjo Kang; Eun Sun Jung; Su Jin Won; Eun Hye Kim; Yu Kyeong Kim; Dong Young Lee; Inhee Mook-Jung
Journal:  Alzheimers Res Ther       Date:  2017-03-22       Impact factor: 6.982

9.  The clinical use of blood-test factors for Alzheimer's disease: improving the prediction of cerebral amyloid deposition by the QPLEXTM Alz plus assay kit.

Authors:  Haeng Jun Kim; Jong-Chan Park; Keum Sim Jung; Jiyeong Kim; Ji Sung Jang; Sunghoon Kwon; Min Soo Byun; Dahyun Yi; Gihwan Byeon; Gijung Jung; Yu Kyeong Kim; Dong Young Lee; Sun-Ho Han; Inhee Mook-Jung
Journal:  Exp Mol Med       Date:  2021-06-09       Impact factor: 8.718

Review 10.  Proximate Mediators of Microvascular Dysfunction at the Blood-Brain Barrier: Neuroinflammatory Pathways to Neurodegeneration.

Authors:  Barry W Festoff; Ravi K Sajja; Luca Cucullo
Journal:  Biomed Res Int       Date:  2017-08-14       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.